Presenting translational data at a prestigious meeting like ASGCT is a significant positive development for Voyager Therapeutics. It not only highlights the progress of their CNS gene therapy programs towards clinical trials but also potentially enhances the company's visibility and credibility in the biotech and investor communities. This could lead to increased investor confidence and a positive short-term impact on the stock price.